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heart disease, stroke, transient ischemic attack, peripheral artery disease, any revascularization procedure, or a prescription for any of the following medications: antiarrhythmics (class I and III), selective calcium-channel blockers with direct cardiac effects, digitalis, nitrates, and vitamin K antagonists.
Study Design and Follow-Up
We conducted an historical open cohort study from July 2006 to December 2011. Study entry for patients who fulfilled inclusion criteria was the date of first Information System for Research Development in Primary Care-recorded blood pressure (BP) measurement during the study period. Censoring was applied at the earliest date of AF diagnosis, death, transfer from Information System for Research Development in Primary Care, or end of study period.
Variable Definition
We identified patients with new-onset AF according to International Classification of Diseases (ICD) codes, Ninth and Tenth revision: I48 (ICD-10) and 4273 and subcategories (ICD-9). Patients were defined as hypertensive if they had previous hypertension without target organ involvement (I10, I15 in ICD-10; 401 in ICD-9) or were receiving antihypertensive treatment (adrenergic β-antagonists, diuretics, calcium-channel blockers, or agents acting on the renin-angiotensin system).
The following covariates were potential predictors or confounders:
1. Age.Sex. 2. Mortality in small Spanish areas and socioeconomic and environmental (MEDEA) deprivation index. 12 3. Systolic and diastolic BP (in mm Hg); all centers follow standardized methods for such measurements. 13 4. Pulse pressure (mm Hg).
Smoking habit (yes/no).
6. Alcohol consumption (no/low risk/high risk). 7. Body mass index (kg/m 2 ). 8. Diabetes mellitus (yes/no) or record of antidiabetic drug purchases. 9. Comorbidities (yes/no): chronic kidney disease, hyperthyroidism, hypothyroidism, sleep apnea, valvular heart disease, and heart failure. 10. Drug use: antihypertensives, antidiabetics, statins, and lipid-lowering drugs other than statins.
11. Laboratory tests: glucose; triglycerides; total, highdensity lipoprotein, and low-density lipoprotein cholesterol. 12. Other measurements: weight and height.
Statistics
Continuous variables were presented as mean (SD) and categorical variables as frequencies (percentages). We used 10 multiple imputations by chained equations 14 to replace baseline missing values of systolic BP, diastolic BP, pulse pressure, weight, height, body mass index, glucose, triglycerides and total, high-density lipoprotein, and low-density lipoprotein cholesterol. We performed a complete-case analysis and compared it with the results based on multiple imputation. The specific population characteristics made the missing-atrandom assumption plausible (see Annex S1 for validation of the imputation process).
To build and validate the risk function, patient records were randomly divided between derivation and validation data sets ( Figure 1 ). We selected 40% of the data as the validation data set, using computerized random sampling without replacement of the population who met inclusion criteria; the remaining 60% constituted the derivation data set (data sets compared with Tables S3 and S4 ).
Model Derivation
Cox proportional hazards regression was used to derive the AF incidence risk function. We tested the proportionality of hazards assumption and the linearity of continuous variables with respect to the end point.
Variables and risk factors were selected for the final model based on clinical relevance 1, 15, 16 and statistical significance (defined as P<0.01). Details on the bootstrap modeling are presented in Annex S1.
Several preliminary models were built by organizing variables and subgroups of variables according to their frequency of inclusion in the bootstrap models. We compared the C-index, BIC (Schwartz's Bayesian information criterion), and Aikaike's information criterion 17 to determine performance and select the final model. To test model stability, we also examined the distribution of the bootstrap regression coefficients for each variable. 17 To adjust the model, we calculated the Brier score at multiple time points, created a time-dependent curve, and compared it with a null model as the benchmark.
18

Model Validation
We evaluated accuracy and reliability of the risk function following standard methodology (Annex S1).
All analyses were conducted using R Statistical Package (version 3.0.1; R Foundation for Statistical Computing, Vienna, Austria).
Results
Study Population
Between July 1, 2006, and December 31, 2011, Information System for Research Development in Primary Care recorded 580 219 hypertensive patients. After exclusion criteria were applied (Figure 1 ), 255 440 remained for analysis. Table 1 displays baseline characteristics of the study population; the whole population is shown in Table S5 . The mean age was 66.87 (9.45) years. Individuals with new-onset AF had lower prevalence of smoking and alcohol consumption, higher prevalence of cardiac comorbidities, and better lipid profile at the time of inclusion. 
Population Characteristics
Incidence
We obtained an incidence of 7.24 per 1000 person-years (95% confidence interval, 7.08-7.40); 7668 new-onset AF events occurred (3% of the 255 440 participants) over the median follow-up of 4.1 years.
Model Derivation
The following variables entered the final model (Table 2) : age, weight, total cholesterol, heart failure, valvular heart disease, and antihypertensive drugs other than agents acting on the renin-angiotensin system. The final equation to estimate individual 5-year risk of new-onset AF 19 is shown in Annex S1; Figure S2 summarizes the probability of new-onset AF for individuals at different levels of the explanatory variables. 20 In addition, Table S7 displays the candidate variables for multivariate modeling and their age-adjusted hazard ratios for new-onset AF; frequency of entering the bootstrap models is shown in Table S8 . The variables shaping the final model were clustered 97% of the time; adding more variables to this final model did not notably improve performance. A comparisonin the derivation data set-of the performance of models built with variables that entered the bootstrap models is shown in Table S9 . Coefficients of the variables that entered the final model were of the same sign in 100% of the bootstrap models. Finally, model adjustment was graphed as Brier score timedependent curves ( Figure S1 ).
Model Validation
The concordance index (C-index; SE) of the final model was 0.769 (0.004) in the derivation data set and 0.768 (0.005) in the validation data set. A Forest plot (Figure 2 ) of the coefficients and their 95% confidence interval between the derivation and validation datasets shows their overlap. Figure 3 contrasts deciles of predicted risks (with the risk function) of new-onset AF against observed estimates (of the KaplanMeier function), 21 using the validation data set.
Interactions
We tested for plausible interactions, but they did not improve the prediction of the final model (data not shown) and were not included.
Discussion
Main Findings
We have developed a risk function that predicts risk of newonset AF in hypertensive individuals without ischemic vascular disease, aged ≥55 years. It is purposefully based on variables commonly examined in daily practice. Furthermore, its performance is solid, as evidenced by its discriminative ability and calibration. The use of risk functions to identify high-risk individuals is a key strategy in primary prevention of cardiovascular diseases. 22 The absolute cardiovascular disease risk reduction is more efficient when applied to these high-risk individuals. 23 About AF in particular, statin therapy in elderly patients with hypertension seemed to be beneficial within a high-risk group, as identified by CHADS 2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient Entire data set. Data are shown as % unless otherwise specified. AF indicates atrial fibrillation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; HDL, high density lipoprotein; LDL, low density lipoprotein; MEDEA, socioeconomic deprivation index; and n, number of cases.
*Shown as mean (SD). †Selective calcium-channel blockers with mainly vascular effects. ‡One or more of the following: diuretics, β-blocking agents, calcium-channel blockers †, other antihypertensives (but distinct from agents acting on the reninangiotensin system).
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Additional research is needed to compare the results of specific interventions in individuals at different risk levels. Risk analysis in this population might also be valuable to strengthen and individualize lifestyle recommendations, treatment decisions, and the relevance of more aggressive monitoring with additional electrocardiographic or echocardiographic variables in specific patients, or even to study the effects of upstream therapies in the primary prevention of new-onset AF.
Previous Studies
The characteristics of our study population concur with some reported in similar populations. 15, 25 The AF incidence we found also compares with some previous studies in the hypertensive population although incidence rates vary widely. 15, 26, 27 The existing risk functions for AF incidence prediction were mostly built on the general population, 20, 21, 28, 29 thus including patients with prevalent ischemic vascular disease. We excluded patients with prevalent ischemic vascular diseases because they could plausibly have an indication such as statins in secondary prevention of myocardial infarction and therefore be taking the same drugs that could be prescribed in primary prevention of AF.
Studies assessing new-onset AF risk within hypertensive populations are scarce and have focused on electrocardiographic variables. 15, 27 We intentionally built the model with no electrocardiographic or echocardiographic variables, to allow prompt risk assessment for new-onset AF in the primary care setting. Only Schnabel et al 20 studied a hypertensive subgroup of their study population using clinical variables, but they still included patients with previous myocardial infarction.
The performance of the risk prediction model is sound, and its C-index is in the upper range when compared with other previously validated risk prediction models. 20, 21, 28, 30 To extend the model's external validity, further validation in populations from other countries would be needed.
With regard to the variables framing the model, age was a prominent risk factor for new-onset AF, in full agreement with previous reports. 15, 20, 21, [27] [28] [29] The consideration of sex as a predictor stirs more controversy: we did not include it, coinciding with the Atherosclerosis Risk in Communities (ARIC) 28 and CHARGE-AF (Cohorts for Heart and Aging Research in Genomic Epidemiology atrial fibrillation) Consortium 21 studies, whereas it entered the predictive and explanatory models of the Framingham Heart Study 20 and the Busselton Health Study, 29 respectively. The age and sex interaction, also previously observed, 20, 29 did not improve the predictive capacity of our model.
Including weight in the model aligns with previous findings that consider it an important risk factor 31 -and it is modifiable, which highlights weight reduction as a lifestyle recommendation for AF prevention; for example, the primary care team could strengthen or schedule recommendations about dieting. Such weight loss would not only apply to the obese, but to any weight reduction within healthy boundaries. However, this disagrees with the Busselton Health Study, in which height prevailed over body mass index when explaining the risk of AF incidence. 29 Differences between study populations in age range and inclusion criteria may, in part, account for the conflicting results.
Total cholesterol hazard ratio was associated with lower risk in our function. This association has been described previously 32 but did not reach significance in previous studies of AF prediction models. 20, 21, 28, 29 Our result could be because of higher statistical power with a higher number of cases or perhaps because of our inclusion in the analysis of patients treated with statins. However, this hypothesis requires confirmation.
Heart failure and AF often coexist and predispose to the other. 1 Because hypertension is the primary risk factor for heart failure, 13 individuals with heart failure in our study Figure 2 . Forest plot of the hazard ratio and the corresponding 95% confidence interval on the derivation (■) and the validation (□) data set. *One or more of the following: diuretics, β-blocking agents, calcium-channel blockers (selective, with mainly vascular effects), other antihypertensives (but distinct from agents acting on the renin-angiotensin system). Derivation data set (P<0.01). CI indicates confidence interval; and HR, hazard ratio.
*HRs are expressed per 1 unit increase in continuous variables, and for the presence of the condition in dichotomous variables.
†One or more of the following: diuretics, β-blocking agents, calciumchannel blockers (selective calcium-channel blockers with mainly vascular effects), other antihypertensives (but distinct from agents acting on the reninangiotensin system).
by guest on April 15, 2017 http://hyper.ahajournals.org/ Downloaded from (elderly hypertensives) are at particularly high risk of newonset AF. They would likely be the subgroup who would most benefit from any primary prevention intervention.
Valvular heart disease provides one of the highest hazard ratios for AF incidence in the risk function. Tighter control of modifiable conditions of new-onset AF in these individuals may avoid or delay more aggressive procedures. For example, it has been recommended that surgery be considered in patients with asymptomatic valvular heart disease and preserved left ventricle function who have new-onset AF 33 . In some of these cases, AF prevention might avoid the need for surgery.
Antihypertensive treatment increased the AF risk, probably because of an indication bias. However, treatment with agents acting on the renin-angiotensin system did not enter the bootstrap models when we examined antihypertensive treatment separately (data not shown). Hence, we grouped antihypertensive treatment without including them. A new-users design (as opposed to the prevalent-users design we used) might elucidate whether any medication could prevent from having new-onset AF.
Some other variables-BP measurements, alcohol consumption, and diabetes mellitus-did not enter the final model either, because of their perhaps unexpected low frequency in the bootstrap models.
BP measurements could be affected by an indication bias, suggested by the above-mentioned positive sign of the antihypertensive treatment hazard ratios. Of the 3 BP variables we examined, pulse pressure more often entered the bootstrapping models (Table S8) , probably because it integrates both the systolic BP increase and the diastolic BP decrease that occurs in the elderly, 13 but it did not enter often enough to be included in the final model.
Alcohol intake has been dose-associated with new-onset AF risk. 34 The absence of alcohol intake in our model might be because of the low number of patients in the high-risk consumption group, resulting in lower power for this variable. The risk associated with alcohol intake could also be explained partly by hypertension in our population (hypertensive without vascular heart disease). 34 Diabetes mellitus remains controversial as a predictor of newonset AF. 35 Whereas it has been clearly related to this arrhythmia, 35, 36 its causal relationship is not well established. 35 Some previous reports included diabetes mellitus in their prediction models in general population 21, 28 ; others did not. 15, 29 Again, in our study population, hypertension might partly account for the increased AF risk ascribed to diabetes mellitus.
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Strengths and Limitations
Access to validated, high-quality, electronic medical records 11 provided a large sample size and large number of AF events, reflected real-life conditions, and warranted high external validity. To avoid selection bias, we imputed the missing values for continuous variables, instead of excluding records with missing data. 21 We also acknowledge several limitations. First, data were retrospectively examined but prospectively recorded. Second, AF under-reporting remained a difficulty to overcome, 1,37 and perhaps not all patients consulted their doctor: linking the primary care records database with hospital discharge registries would have captured some of these cases. Nonetheless, we observed an AF incidence within the wide range previously reported in similar populations. 15, 26, 27 Third, sleep apnea may have also been under-reported, resulting in lower prevalence and lack of power to enter the final model. 38 However, hypertension might also help to explain the risk of new-onset AF associated with this sleep disturbance. 39 Fourth, some residual confounding may have remained. To handle this possibility, we carefully contemplated all possible variables for which the model required adjustment; delimiting the population for newonset AF risk estimation (instead of using a model built for general population) also lessened this effect. Fifth, we defined a new-onset AF as the first diagnosis of AF, regardless of whether it became permanent; we could not distinguish between AF types because we used ICD-coded diagnoses. Finally, the codes that define AF are identical to those that define atrial flutter. However, atrial flutter is much less common, and each of these arrhythmias may lead to the other; hence, interventions that prevent AF would also undermine onset of atrial flutter.
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Perspectives
We have built a model we expect could be useful to clinicians and researchers in patient counseling, in choosing accessible diagnostic procedures, and in evaluating potential interventions on AF prevention. To this end, we intentionally included variables commonly used within primary care settings. What Is New?
Sources of Funding
• Some studies have previously examined the risk of new-onset atrial fibrillation (AF) in general population, in population with ischemic heart disease, heart failure, or in hypertensive population. But all of them include patients with history of ischemic vascular disease. We delimited this study to patients aged ≥55 years, hypertensive with no history of ischemic heart disease, stroke, or peripheral artery disease. These patients are currently not under AF prevention treatments.
What Is Relevant?
• We built a risk function for a population that could be targeted for primary prevention interventions: hypertensive, aged ≥55 years, without ischemic vascular disease. Our model predicts AF incidence using clinical and laboratory variables that could simply and quickly be assessed in primary care settings.
Summary
We built a risk prediction model for new-onset AF in the hypertensive without ischemic vascular disease, aged ≥55 years. The model performance is solid, in the upper ranges when compared with other AF prediction models. It was derived using clinical variables readily assessed in primary care settings to facilitate an agile automatic AF risk assessment in this context. Additional research to study more intensive monitoring in those patients with high-risk scores remains to be assessed.
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Lia Alves-Cabratosa, Maria García-Gil, Marc Comas-Cufí, Anna Ponjoan, Ruth Martí, Dídac Table 2 shows the baseline characteristics of individuals with complete cases and of the completed datasets. Supplementary Table 3 describes the derivation dataset, and Supplementary Table 4 the validation dataset, both with completed and complete cases. Supplementary Table 6 displays the final Cox model fitted from the complete cases subset of data, for comparison with results based on multiple imputation. There are no substantial differences between these datasets. In the pre-multiple imputation stage we checked for normality, extreme values and outliers in continuous variables, correlations and collinearity among those variables with missing data and variables that may be included in multiple imputation. Then, variables related to missing data and/or to the value of missing data were identified. The following variables were included in the imputation models: age, sex, MEDEA (socioeconomic deprivation index), natural logarithm (ln) of the diastolic blood pressure (DBP), ln (pulse pressure), ln (weight), ln (height), obesity, alcohol consumption, smoking, diabetes, ln (glucose), ln (total cholesterol), ln (high density lipoprotein cholesterol), ln (low density lipoprotein cholesterol), ln (triglycerides), dyslipidemia, hyperthyroidism, hypothyroidism, chronic obstructive pulmonary disease, sleep apnea, chronic kidney disease, valvular heart disease, heart failure, diuretics, beta blocking agents, calcium channel blockers, agents acting on the renin angiotensin aldosterone system, other antihypertensives, hypoglycemic agents, statins, lipid-lowering agents other than statins, anti-inflammatory and anti-rheumatic agents, systemic corticosteroids, psycholeptics, and psychoanaleptics. We also included incident atrial fibrillation and the Nelson Aalen estimator of the hazard function 2 . We used the natural logarithmic transformation of the indicated continuous variables included in the imputation models to improve normality of distribution and to avoid the unlikely possibility of imputing any negative numbers. After imputation, variables were transformed back to their original scale.
 Model Derivation. Bootstrap Modeling
We selected 1000 bootstrap samples -100 samples from each imputation-(each sample had N=153264, equaling the derivation dataset), with repetition. The best model was derived from each bootstrap sample, using a forwardbackward algorithm assessed by Schwartz's Bayesian information criterion (BIC). The frequency with which each variable was included in the bootstrap models was counted; and so was the frequency with which subgroups of variables clustered together. Supplementary Table 8 displays the frequency with which each candidate variable entered any of the bootstrap models we built.
 Model Validation
We evaluated accuracy and reliability of the risk function as follows: 1) discrimination study with concordance index (C-index); 2) comparison of coefficients and respective 95% confidence intervals (CI) of the model -built from the derivation dataset-against the validation dataset (Forest plot); 3) examination of calibration plots to contrast risk deciles of the expected against observed values, using the validation dataset.
 Study population
Supplementary Table S5 displays the baseline characteristics of the whole study population.
 Age-adjusted Analysis of new-onset AF Predictors
See Supplementary Table S7 . Supplementary Table 9 compares the performance, -in the derivation datasetof the models built with those variables that entered the bootstrap models.
 Comparison of Models Performance
 Model Adjustment
Model adjustment is graphed in Supplementary Figure S1 . Three curves represent the time-dependent variation of the Brier score 3 for: a null model (dotted line), based on the Brier score for the overall Kaplan-Meier estimator; an age-adjusted model (dashed line); our model (solid line). Our model improves new-onset AF prediction beyond the effect of only age adjustment.
 Prediction Model Equation
The expression for the proportional hazards risk function allowing for more than one covariate is: R(t,x, β)=1-[S 0 (t)] exp(x' β ) where R(t,x, β) is the Risk at a time t, depending on specific covariates x and their estimated coefficients β. S 0 (t) is the baseline survival function at a time t 4 . The risk function, R(t), depending on age, weight, total cholesterol, heart failure, valvular heart disease, and antihypertensive drugs*, without new-onset AF is: R ( t = 5, age, weight, total cholesterol, heart failure, valvular heart disease, antihypertensive drugs)=1−(0.9999824853)exp(y) where y = 0.0973 age (years) + 0.0232 weight (kg) + −0.0055 total cholesterol (mg/dl) + 0.5935 heart failure (yes/no) + 0.791 valvular heart disease (yes/no) + 0.1731 antihypertensive drugs (yes/no)* *antihypertensive drugs: one or more of the following: diuretics, beta blocking agents, calcium channel blockers † , other hypertensives (but distinct from Agents acting on the renin-angiotensin system). † Selective calcium channel blockers with mainly vascular effects.
Supplementary Figure 2 summarizes the probability of new-onset AF in subjects with different levels of the explanatory variables 5 .
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. Missing values for the imputed variables within the entire population, for the incident AF cases, and for the cases without new-onset AF Data are shown as % unless otherwise specified. AIC, Aikaike's information criterion; BIC, Schwartz's Bayesian information criterion; COPD, chronic obstructive pulmonary disease.
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